Clinical trial
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to…
NCT00496470 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00496470 |
|---|---|
| Title | Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD. |
| Official title | A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease, COPD |
| Intervention type | Drug |
| Interventions | Symbicort (budesonide/formoterol turbuhaler 320/9ug), Spiriva (tiotropium bromide 18ug) |
| Enrollment | 660 |
| Start date | May 1, 2007 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Jul 4, 2007 |
| Last update posted | Nov 9, 2012 |
| Countries | Australia, Canada, France, Germany, Hungary, Poland, Slovakia, Spain, Sweden |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: